Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method

Nucleic Acids Research

Volumn 35, Issue 5, 2007, Pages

  Liu, Zhongfa ^a,b   Liu, Shujun ^a,b   Xie, Zhiliang ^a,b   Blum, William ^a,b   Perrotti, Danilo ^a,b   Paschka, Peter ^a,b   Klisovic, Rebecca ^a,b   Byrd, John ^a,b   Chan, Kenneth K ^a,b   Marcucci, Guido ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5 METHYLDEOXYCYTIDINE; DEOXYGUANOSINE DERIVATIVE; FR 901228; GENOMIC DNA; 5-METHYLDEOXYCYTIDINE; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; DEOXYCYTIDINE; DEOXYGUANOSINE; DNA (CYTOSINE 5 ) METHYLTRANSFERASE 1; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; DRUG DERIVATIVE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; BONE MARROW BIOPSY; CELL STRAIN K 562; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA METHYLATION; DOSE TIME EFFECT RELATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL LINE; LIQUID CHROMATOGRAPHY; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; PHARMACODYNAMICS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS; ACUTE DISEASE; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; METHODOLOGY; MYELOID LEUKEMIA; PHASE 1 CLINICAL TRIAL; TUMOR CELL LINE; VALIDATION STUDY;

ACUTE DISEASE; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; CLINICAL TRIALS, PHASE I; DEOXYCYTIDINE; DEOXYGUANOSINE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; HUMANS; LEUKEMIA, MYELOID; TANDEM MASS SPECTROMETRY;

EID: 34247094617     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkl1156     Document Type: Article

References (17)

1. Jones,P.A. and Baylin,S.B. (2002) The fundamental role of epigenetic events in cancer., Nat. Rev. Genet., 3, 415-428.
2. Herman,J.G. and Baylin,S.B. (2003) Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med., 349, 2042-2054.
3. Issa,J.P. (2004) CpG island methylator phenotype in cancer. Nat. Rev. Cancer., 4, 988-993.
4. Esteller,M., Fraga,M.F., Guo,M., Garcia-Foncillas,J., Hedenfalk,I., Godwin,A.K., Trojan,J., Vaurs-Barriere,C., Bignon,Y.J. et al. (2001) DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum. Mol. Genet., 10, 3001-3007.
5. Lubbert,M. (2000) DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: Clinical results and possible mechanisms of action. Curr. Top Microbiol Immunol., 249, 135-164.
6. Daskalakis,M., Nguyen,T.T., Nguyen,C., Guldberg,P., Kohler,G., Wijermans,P., Jones,P.A. and Lubbert,M. (2002) Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2-deoxycytidine (decitabine) treatment. Blood, 100, 2957-2964.
7. Issa,J.P., Gharibyan,V., Cortes,J., Jelinek,J., Morris,G., Verstovsek,S., Talpaz,M., Garcia-Manero,G. and Kantarjian,H.M. (2005) Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J. Clin. Oncol. 23, 3948-3956.
8. Mund,C., Hackanson,B., Stresemann,C., Lubbert,M. and Lyko,F. (2005) Characterization of DNA demethylation effects induced by 5-Aza-2′-deoxycytidine in patients with myelodysplastic syndrome. Cancer Res., 65, 7086-7090.
9. Samlowski,W.E., Leachman,S.A., Wade,M., Cassidy,P., Porter-Gill,P., Busby,L., Wheeler,R., Boucher,K., Fitzpatrick,F. et al. (2005) Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. J. Clin. Oncol., 23, 3897-3905.
10. Gehrke,C.W., McCune,R.A., Gama-Sosa,M.A., Ehrlich,M. and Kuo,K.C. (1984) Quantitative reversed-phase high-performance liquid chromatography of major and modified nucleosides in DNA. J. Chromatogr., 301, 199-219.
11. Song,L., James,S.R., Kazim,L. and Karpf,A.R. (2005) Specific method for the determination of genomic DNA methylation by liquid chromatography-electrospray ionization tandem mass spectrometry. Anal. Chem., 77, 504-510.
12. Cohen,N., Dagan,T., Stone,L. and Graur,T. (2005) GC composition of the human genome: In search of isochors. Mol. Biol. Evol., 22 1260-1272.
13. Bender,C.M., Pao,M.M. and Jones,P.A. (1998) Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res., 58, 95-101.
14. Wirtz,M., Stach,D., Kliem,H.C., Wiessler,M. and Schmitz,O.J. (2004) Quantitative analysis of DNA methylation in chronic lymphocytic leukemia patients. Electrophoresis, 25, 839-845.
15. Kantarjian,H., Issa,J.P., Rosenfeld,C.S., Bennett,J.M., Albitar,M., DiPersio,J., Klimek,V., Slack,J., de Castro,C. et al. (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer, 106, 1794-1803.
16. Liu,Z., Marcucci,G., Byrd,J.C., Grever,M., Xiao,J. and Chan,K.K. (2006) Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2′-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method. Rapid Commun. Mass Spectrom., 20, 1117-1126.
17. Friso,S., Choi,S.W., Dolnikowski,G.G. and Selhub,J. (2002) A method to assess genomic DNA methylation using high-performance liquid chromatography/electrospray ionization mass spectrometry. Anal. Chem. 74, 4526-4531.